Non-small-cell carcinoma of the lung has long been considered a chemotherapeutically resistant neoplasm. Newer agents and combinations are being tested.
Methods
The authors have reviewed data on recent and active phase I and phase II trials of several new agents and combinations.
Results
New drugs that affect both response rates and survival include vinorelbine, paclitaxel, docetaxel, gemcitabine, topotecan, and irinotecan.
Conclusions
The advent of several relatively well-tolerated agents that alone have beneficial effects in advanced non-small-cell lung cancer provides reasonable hope that more effective drug combinations will soon be available for this disease.
Get full access to this article
View all access options for this article.
References
1.
MuersM.F., HawardR.A.Management of lung cancer. Thorax.1996; 51: 557–560.
2.
ArndtK., CoyP., SchaafsmaJ.Implicit rationing criteria in non-small-cell lung cancer treatment. Br J Cancer.1996; 73: 781–788.
3.
BrownJ.S., ErautD., TraskC.Age and the treatment of lung cancer. Thorax.1996; 51: 564–568.
4.
SlevinM.L., StubbsL., PlantH.J.Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. Br Med J.1990; 300: 1458–1460.
5.
RabyB., PaterJ., MackillopW.J.Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J Clin Oncol.1995; 13: 1904–1911.
6.
MackillopW.J., WardG.K., O'SullivanB.The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. Br J Cancer.1986; 54: 661–667.
7.
EvansW.K., WillB.P., BerthelotJ.M.Estimating the cost of lung cancer diagnosis and treatment in Canada: the POHEM model. Can J Oncol.1995; 5: 408–419.
8.
Non-small Cell Lung Cancer Collaborative Group.Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J.1995; 311: 899–909.
9.
EllisP.A., SmithI.E., HardyJ.R.Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer.1995; 71: 366–370.
10.
TummarelloD., GrazianoF., IsidoriP.Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol.1995; 35: 249–253.
11.
JaakkimainenL., GoodwinP.J., PaterJ.Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol.1990; 8: 1301–1309.
12.
SmithT.J., HillnerB.E., DeschC.E.Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis. J Natl Cancer Inst.1993; 85: 1460–1474.
13.
KrikorianA., BreilloutF.Vinorelbine (Navelbine): a new semisynthetic vinca alkaloid. Onkologie.1991; 14: 7–12.
14.
RowinskyE.K., DonehowerR.C.Antimicrotubule agents. In: ChabnerB.A., LongoD.L., eds. Cancer Chemotherapy and Biotherapy.Philadelphia, Pa: Lippincott-Raven; 1996: 263–296.
15.
DepierreA., LemarieE., DabouisG.A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol.1991; 14: 115–119.
16.
YokoyamaA., FuruseK., NiitaniH.Multi-institutional phase II trial of Navelbine (vinorelbine) in non-small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol.1992; 11: A957.
17.
FuruseK., KubotaK., KawaharaM.Japan Navelbine Lung Cancer Study Group. A phase II study of Navelbine, a new derivative of vinca alkaloid, for previously untreated non-small cell lung cancer. Oncology.1997. In press.
18.
Le ChevalierT., BrisgandD., DouillardJ.Y.Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol.1994; 12: 360–367.
19.
DepierreA., ChastangC., QuoixE.Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol.1994; 5: 37–42.
20.
CrawfordJ., O'RourkeM., SchillerJ.H.Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol.1996; 14: 2774–2784.
21.
WozniakA.J., CrowleyJ.J., BalcerzakS.P.Randomized phase III trial of cisplatin (CDDP) vs CDDP plus Navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A1110.
22.
RowinskyE.K., DonehowerR.C.Paclitaxel (Taxol). N Engl J Med.1995; 332: 1004–1014.
23.
LiebmannJ., CookJ.A., FisherJ.In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst.1994; 86: 441–446.
24.
SchillerJ.H., StorerB., TutschK.Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol.1994; 12: 241–248.
25.
ChangA.Y., KimK., GlickJ.Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst.1993; 85: 388–394.
26.
MurphyW.K., FossellaF.V., WinnR.J.Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst.1993; 85: 384–388.
27.
GeorgiadisM.S., RussellE., JohnsonB.E.Prolonging the exposure of human lung cancer cell lines to paclitaxel increases the cytotoxicity. Lung Cancer.1994; 11(suppl 1): 95.
28.
GeorgiadisM.S., SchulerB., JohnsonB.E.Four-day paclitaxel infusion with cisplatin for patients with lung cancer. Semin Oncol.1995; 22(4 suppl 9): 67–69.
29.
GatzemeierU., HeckmayrM., NeuhaussR.Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer.1995; 12(suppl 2): S101–S106.
30.
SekineI., NishiwakiY., WatanabeK.East Japan Paclitaxel Study Group. Phase II study of 3-hour infusion of paclitaxel in previously untreated non-small cell lung cancer. Clin Cancer Res.1996; 2: 941–945.
31.
TesterW.J., JinP.Y., ReardonD.H.Phase II study of patients with metastatic nonsmall cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer.1996; 79: 724–729.
32.
HainsworthJ.D., ThompsonD.S., GrecoF.A.Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol.1995; 13: 1609–1614.
33.
MillwardM.J., BishopJ.F., FriedlanderM.Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol.1996; 14: 142–148.
34.
JekunenA.P., ChristenR.D., ShalinskyD.R.Synergistic interaction between cisplatin and Taxol in human ovarian carcinoma cells in vitro. Br J Cancer.1994; 69: 299–306.
35.
RowinskyE.K., GilbertM.R., McGuireW.P.Sequences of Taxol and cisplatin: a phase I and pharmcologic study. J Clin Oncol.1991; 9: 1692–1703.
36.
RowinskyE.K., ChaudhryV., ForastiereA.A.Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol.1993; 11: 2010–2020.
37.
BonomiP., KimK., ChangA.Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer: an Eastern Cooperative Group (ECOG) trial. Proc Annu Meet Am Soc Clin Oncol.1996; 15: A1145.
38.
GiacconeG., SplinterT., PostmusP.Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A1109.
39.
LangerC.J., LeightonJ.C., ComisR.L.Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer (NSCLC): a phase II toxicity, response, and survival analysis. J Clin Oncol.1995; 13: 1860–1870.
40.
JohnsonD.H., PaulD.M., HandeK.R.Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol.1996; 14: 2054–2060.
41.
RowinskyE.K., FloodW.A., SartoriusS.E.Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Semin Oncol.1995; 22(4 suppl 9): 48–54.
42.
VafaiD., IsraelV., ZaretskyS.Phase I/II trial of combination carboplatin and Taxol in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1067.
FromesY., GounonP., VeitiaR.Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel. J Protein Chem.1996; 15: 377–388.
45.
RingelI., HorwitzS.B.Studies with RP 56976 (Taxotere): a semisynthetic analogue of Taxol. J Natl Cancer Inst.1991; 83: 288–291.
AaproM., BraakhuisB., DietelM.Superior activity of Taxotere (TER) over Taxol (TOL) in vitro. Proc Annu Meet Am Assoc Clin Res.1992; 33: A3086.
48.
VogelM., HilsenbeckS.G., DepenbrockH.Preclinical activity of Taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with Taxol and conventional antineoplastic agents. Eur J Cancer.1993; 29A: 2009–2014.
49.
FossellaF.V., LeeJ.S., MurphyW.K.Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol.1994; 12: 1238–1244.
50.
FrancisP.A., RigasJ.R., KrisM.G.Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol.1994; 12: 1232–1237.
51.
CernyT., WandersJ., KaplanS.Taxotere is an active drug in non-small cell lung cancer (NSCLC): a phase II trial of the Early Clinical Trials Group. Proc Annu Meet Am Soc Clin Oncol.1993; 12: 331.
52.
BurrisH., EckardtJ., FieldsS.Phase II trials of Taxotere in patients with non-small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol.1993; 12: A1116.
53.
MillerV.A., RigasJ.R., FrancisP.A.Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer.1995; 75: 968–972.
54.
Le ChevalierT., BelliL., MonnierA.Phase II study of docetaxel (Taxotere) and cisplatin in advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1059.
55.
ColeJ.T., GrallaR.J., MarquesC.B.Phase I-II study of cisplatin plus docetaxel (Taxotere) in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1087.
56.
VrignaudP., BayssasM., LavelleF.Preclinical in vivo activity of docetaxel-containing combinations. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1599.
57.
IhdeD.C.Chemotherapy of lung cancer. N Engl J Med.1992; 327: 1434–1441.
58.
MurphyW.K., WinnR.J., HuberM.Phase II study of Taxol (T) in patients (pts) with non-small cell lung cancer (NSCLC) who have failed platinum (P) containing chemotherapy (Ctx). Proc Annu Meet Am Soc Clin Oncol.1994; 13: A1224.
59.
FossellaF.V., LeeJ.S., ShinD.M.Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol.1995; 13: 645–651.
60.
RuckdeschelJ., WagnerH.Jr, WilliamsC.Second-line chemotherapy for resistant, metastatic, non-small cell lung cancer (NSCLC): the role of Taxol (TAX). Proc Annu Meet Am Soc Clin Oncol.1994; 13: A1200.
61.
HeinemannV., HertelL.W., GrindeyG.B.Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxy-cytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res.1988; 48: 4024–4031.
62.
HertelL.W., BoderG.B., KroinJ.S.Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res.1990; 50: 4417–4422.
63.
XuY.Z., PlunkettW.Regulation of dCMP deaminase in intact CCRF-CEM cells. Proc Annu Meet Am Assoc Clin Res.1990; 31: A2402.
64.
AbrattR.P., BezwodaW.R., FalksonG.Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol.1994; 12: 1535–1540.
65.
AndersonH., LundB., BachF.Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol.1994; 12: 1821–1826.
66.
ShepherdF.A., GatzemeierU., GotfriedM.An extended phase II study of gemcitabine in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1993; 12: A1096.
67.
FossellaF., LippmanS., PangA.Phase I/II study of gemcitabine by 30 min weekly IV infusion x 3 wk every 4 wk for non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1993; 12: A1082.
68.
CormierY., EisenhauerE., MuldalA.Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): a study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol.1994; 5: 283–285.
69.
TanzerL.R., RutherfordP.G., SelfT.D.Antitumor activity of gemcitabine in combination with cisplatin against the human NSCLC xenograft Calu-6. Proc Annu Meet Am Assoc Clin Res.1995; 36: A1761.
70.
NakamuraH., YamajiY., FujitaT.Synergistic growth inhibition of gemcitabine/cisplatin, and gemcitabine/etoposide on a human lung cancer cell line, RERF-LC-OK. Proc Annu Meet Am Assoc Clin Res.1995; 36: A2425.
71.
TsaiC.M., ChangK.T., ChenJ.Y.Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res.1996; 56: 794–801.
72.
CormierY., ShepherdF., BurkesR.Phase I study of gemcitabine (GEM) and cisplatin (CP) for advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1994; 13: A1140.
73.
DunlopD.J., CameronC., DabouisG.Phase I dose-escalation study of cisplatin in combination with gemcitabine in non-small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol.1994; 13: A1139.
74.
SandlerA.B., AnsariR., McCleanJ.A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1089.
75.
CrinoL., ScagliottaG., MarangoloM.Cisplatin-gemcitabine combination in non-small cell lung cancer (NSCLC): a phase II study. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1066.
76.
StewardW.P., DunlopD.J., CameronC.Phase I/II study of cisplatin with gemcitabine in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1064.
77.
AntonA., CarratoA., Gonzalez LarribaJ.L.Phase II activity of gemcitabine in combination with cisplatin in advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A1134.
78.
ShepherdF., CormierY., EvansW.A phase II study of gemcitabine and cisplatin weekly x 3 every 4 weeks in patients with non-small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol.1996; 15: 380.
79.
AbrattR.P., BezwodaW.R., GoedhalsL.Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1996; 15: A1136.
80.
WallM.E., WaniM.C.Camptothecin and Taxol: discovery to clinic - thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res.1995; 55: 753–760.
81.
HsiangY.H., HertzbergR., HechtS.Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem.1985; 260: 14873–14878.
82.
LynchT.J.Jr, KalishL., StraussG.Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol.1994; 12: 347–352.
83.
Perez-SolerR., FossellaF.V., GlissonB.S.Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol.1996; 14: 503–513.
84.
WeitzJ.J., JungS.H., MarschkeR.F.Jr. Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): a North Central Cancer Treatment Group (NCCTG) trial. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1053.
85.
MasudaN., FukuokaM., KusunokiY.CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol.1992; 10: 1225–1229.
86.
MasudaN., FukuokaM., KudohS.Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol.1994; 12: 1833–1841.
87.
MasudaN., FukuokaM., KudohS.Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer.1993; 68: 777–782.
88.
NakaiH., FukuokaM., FuruseK.An early phase II study of CPT-11 in primary lung cancer [in Japanese]. Gan to Kagaku Ryoho [Jpn J Cancer Chemother].1991; 18: 607–612.
89.
NegoroS., FukuokaM., NiitaniH.[A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group]. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy].1991; 18: 1013–1019.
90.
FukuokaM., NiitaniH., SuzukiA.A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol.1992; 10: 16–20.
91.
DouillardJ.Y., IbrahimN., RiviereA.Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1118.
92.
KudohS., TakadaM., MasudaN.Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res.1993; 84: 203–207.
93.
MasudaN., FukuokaM., TakadaM.CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol.1992; 10: 1775–1780.
94.
SaltzL., KanowitzJ., KelsenD.Phase I study of weekly cisplatin plus irinotecan in patients with advanced solid tumors. Proc Annu Meet Am Soc Clin Oncol.1996; 15: 484.
95.
CernyT., KaplanS., PavlidisN.Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br J Cancer.1994; 70: 384–387.
96.
ShepherdF.A.Phase II trials of single-agent activity of gem-citabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs.1995; 6(suppl 6): 19–25.
97.
NegoroS., FukuokaM., KuritaY.Results of phase II studies of gemcitabine in non-small cell lung cancer (NSCLC). Proc Annu Meet Am Soc Clin Oncol.1994; 13: A1239.
98.
BegbieS.D., HuiR., LeviJ.A.Initial experience with gemcitabine for non-small cell lung cancer (NSCLC) in Australia. Proc Annu Meet Am Soc Clin Oncol.1995; 14: A1172.
